Effective GH Replacement with Somapacitan in Children with GHD: REAL4 2-year Results and after Switch from Daily GH.

Bradley S MillerJoanne C BlairMichael Højby RasmussenAristides ManiatisJun MoriVolker BöttcherHo-Seong KimRikke Beck BangMichel PolakReiko Horikawa

Published in: The Journal of clinical endocrinology and metabolism (2023)

Somapacitan in children with GHD showed sustained efficacy and tolerability for 2 years, and after switching from daily GH. Patients/caregivers switching from daily GH expressed a preference for somapacitan.

Keyphrases

growth hormone
physical activity
end stage renal disease
young adults
ejection fraction
chronic kidney disease
newly diagnosed
palliative care
randomized controlled trial
open label